Design Therapeutics Stock Alpha and Beta Analysis

DSGN Stock  USD 5.97  0.18  2.93%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Design Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Design Therapeutics over a specified time horizon. Remember, high Design Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Design Therapeutics' market risk premium analysis include:
Beta
2.46
Alpha
0.16
Risk
5.7
Sharpe Ratio
0.0933
Expected Return
0.53
Please note that although Design Therapeutics alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Design Therapeutics did 0.16  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Design Therapeutics stock's relative risk over its benchmark. Design Therapeutics has a beta of 2.46  . As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Design Therapeutics will likely underperform. At this time, Design Therapeutics' Price Book Value Ratio is very stable compared to the past year. As of the 29th of November 2024, Price Fair Value is likely to grow to 0.56, while Book Value Per Share is likely to drop 2.98.
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Design Therapeutics Backtesting, Design Therapeutics Valuation, Design Therapeutics Correlation, Design Therapeutics Hype Analysis, Design Therapeutics Volatility, Design Therapeutics History and analyze Design Therapeutics Performance.
To learn how to invest in Design Stock, please use our How to Invest in Design Therapeutics guide.

Design Therapeutics Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Design Therapeutics market risk premium is the additional return an investor will receive from holding Design Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Design Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Design Therapeutics' performance over market.
α0.16   β2.46

Design Therapeutics expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Design Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Design Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Design Therapeutics Market Price Analysis

Market price analysis indicators help investors to evaluate how Design Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Design Therapeutics shares will generate the highest return on investment. By understating and applying Design Therapeutics stock market price indicators, traders can identify Design Therapeutics position entry and exit signals to maximize returns.

Design Therapeutics Return and Market Media

The median price of Design Therapeutics for the period between Sat, Aug 31, 2024 and Fri, Nov 29, 2024 is 5.48 with a coefficient of variation of 9.91. The daily time series for the period is distributed with a sample standard deviation of 0.54, arithmetic mean of 5.44, and mean deviation of 0.4. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
Acquisition by William Arsani of 15000 shares of Design Therapeutics subject to Rule 16b-3
09/05/2024
2
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
09/10/2024
3
On The My Stocks Page - Stock Traders Daily
09/26/2024
4
Point72 Asset Management L.P. Has 3.32 Million Holdings in Design Therapeutics, Inc. - MarketBeat
10/03/2024
5
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
11/07/2024
6
Technical Data - Stock Traders Daily
11/18/2024

About Design Therapeutics Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Design or other stocks. Alpha measures the amount that position in Design Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2023 2024 (projected)
Graham Number11.546.01
Receivables Turnover0.02030.0181

Design Therapeutics Upcoming Company Events

As portrayed in its financial statements, the presentation of Design Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Design Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Design Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Design Therapeutics. Please utilize our Beneish M Score to check the likelihood of Design Therapeutics' management manipulating its earnings.
12th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Design Therapeutics

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Design Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Design Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Design Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Design Therapeutics Stock:
Design Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Design Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Design Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...